In short, these findings suggest that ARPC2 may have distinct prognostic roles in different cancer types and that ARPC2 expression could be a promising prognostic marker in patients with ACC, HNSC, KIRC, KIRP, LIHC, LGG, MESO, PAAD, UCEC, and UVM. This evidence concerns the gene ARPC2 and pancreatic adenocarcinoma.